Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Name

Click to order products ascending

Display 45 Products per page

2014 Community-Acquired Pneumonia Pulse

$599.00

We performed a 5-question survey of 20 infectious disease (ID) specialists in the U.S. to gauge current prescribing practices for community-acquired pneumonia (CAP) and gauge interest in new drugs/new drug candidates.
December 18, 2014
Find out more
2014 October Dermatology Survey

$599.00

We performed a 5-question survey of 21 dermatologists to gauge usage of drugs and devices for the treatment of common dermatological conditions and for aesthetic procedures.
October 30, 2014
Find out more
2015 Breast Cancer Pulse #1

$599.00

This five-question survey of oncologists focuses on treatments for metastatic or locally advanced, HR+/HER2- breast cancer.
May 13, 2015
Find out more
2015 Breast Cancer Pulse #2

$599.00

This 5-question pulse of 24 oncologists practicing in the United States focuses on the usage of HER2-targeted agents for the treatment of breast cancer.
May 26, 2015
Find out more
2015 Breast Cancer Pulse #3

$599.00

We performed a 5-question survey of 25 oncologists in the US to gauge current prescribing practices for breast cancer treatments.
June 12, 2015
Find out more
2015 Cancer Drug Pricing Surveys

$799.00

We performed two 5-question surveys of oncologists in the US to gauge the impact of cancer treatment costs on prescribed therapies.
August 10, 2015
Find out more
2015 Chronic Lymphocytic Leukemia (CLL) KOL Interview

$599.00

Following our live coverage of ASH, we interviewed a KOL who specializes in treating lymphoid malignancies to provide further insight on current and future paradigms for the treatment of CLL and NHLs.
January 28, 2015
Find out more
2015 Chronic Lymphocytic Leukemia (CLL) Pulse

$599.00

We performed a 5-question survey of 40 hematology-oncology specialists in the US to gauge current prescribing practices and physician experience with reimbursement for ibrutinib and idelalisib for the treatment of patients with CLL.
January 27, 2015
Find out more
2015 Jardiance EMPA-REG CVOT Pulse

$599.00

This 5-question survey of 30 primary care physicians and 29 endocrinologists in the United States evaluates the impact of the EMPA-REG cardiovascular outcomes trial (CVOT) of SGLT2 inhibitor Jardiance (Boehringer, LLY).
November 1, 2015
Find out more
2015 PCSK9 Inhibitors Pulse

$599.00

Following the approval of the first PCSK9 Inhibitor, Praluent (SNY, REGN), this 5- question survey of 23 cardiologists evaluated attitudes towards the class, projected usage prior to their CVOTs depending on insurance prior authorization, preference of Praluent vs Repatha (AMGN), and how the oral CETP inhibitors would impact PCSK9 usage under different outcomes study scenarios.
August 19, 2015
Find out more
2015 Post-AAIC KOL Interview

$599.00

Following the 2015 Alzheimer’s Association International Conference (AAIC), we interviewed an Alzheimer’s Disease expert on his opinion of the data presentations and the future of Alzheimer’s Disease treatment.
August 1, 2015
Find out more
2016 Biomedtracker ASCO Survey

$599.00

Biomedtracker performed a 5-question survey of 39 United States and European (France, Germany, Italy, and United Kingdom) oncologists after the American Society of Clinical Oncology (ASCO) meeting to gauge interest in new data presented on drugs in clinical development.
June 8, 2016
Find out more
2016 Biomedtracker Post-EASL Hepatitis C Survey

$599.00

We performed a 9-question survey of 29 EU and 31 US hepatologists and gastroenterologists after the European Association of the Study of the Liver (EASL) International Liver Conference (ILC) from April, 2016 in Barcelona to gauge current and projected prescribing practices for hepatitis C virus (HCV) infection.
May 16, 2016
Find out more
2016 M&A Analysis

$3,000.00

Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how

they may influence the market and future deal-making.
September 7, 2016
Find out more
2016 Post-AHA Report

$5,000.00

The American Heart Association (AHA) Scientific Sessions 2016 was held in New Orleans, LA from November 12-16. The most interesting results were from PCSK9 inhibitors, with details from Repatha’s positive atherosclerosis imaging study and Phase II data.
December 12, 2016
Find out more
2017 Biomedtracker / Meddevicetracker / Datamonitor Healthcare Post-ACC Report

$599.00

The American College of Cardiology (ACC) 66th Scientific Session was held in Washington, DC from 17–19 March 2017.
April 26, 2017
Find out more
2017 Biomedtracker / Meddevicetracker / Datamonitor Healthcare Post-ESC Report

$4,750.00

The European Society of Cardiology (ESC) Congress 2017 was held in Barcelona, Spain from 26–30 August.
September 14, 2017
Find out more
2018 ASH Pulse Survey

$599.00

This 9-question pulse survey of 102 hematologic oncologists practicing throughout the United States and Europe.
January 2, 2019
Find out more
2018 Biomedtracker Datamonitor Healthcare Post-ASH Report

$599.00

The 60th American Society of Hematology (ASH) Annual Meeting and Exposition was held in San Diego, CA from December 1-4, 2018.
January 3, 2019
Find out more
2019 ASH Pulse Survey

$599.00

This 8-question Pulse survey of 55 hematologic oncologists practicing throughout the United States and Europe asks respondents their thoughts on several topics presented at the 2019 American Society of Hematology (ASH) Annual Meeting. Survey questions and additional resources are listed further below.
January 10, 2020
Find out more
2019 Biomedtracker / Datamonitor Healthcare Post-AAN Report

$2,995.00

The 71st Annual Meeting of the American Academy of Neurology (AAN) was held in Philadelphia, Pennsylvania, from May 4-10, 2019.

May 28, 2019
Find out more
2019 Biomedtracker / Datamonitor Healthcare Post-ASCO Report

$2,995.00

The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, IL from May 31st through June 4th, 2019. This year’s conference was highly varied, with key data presented for drugs in numerous different classes and indications.

June 13, 2019
Find out more
2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report

$4,750.00

The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1, 2019. Conference highlights included new data from PARP inhibitors in ovarian cancer, such as Zejula, Lynparza and veliparib, as well as a follow-up update for KRAS-targeted drug AMG 510 for colorectal cancer, and CDK4/6-inhibitors, Kisqali and Verzenio, for breast cancer. Key pipeline updates for more established drugs were highly featured including Keytruda for…
October 18, 2019
Find out more
2019 Post-ADA Report

$2,995.00

The American Diabetes Association (ADA) 79th Scientific Sessions was held in San Francisco, CA from 7–11 June 2019.

July 22, 2019
Find out more
2020 Post-ESMO Report

$4,750.00

The Annual European Society for Medical Oncology (ESMO) 2020 Congress was held virtually from September 19 to September 21, 2020 due to the COVID-19 pandemic.
October 5, 2020
Find out more
5EU Surgical Procedure Volumes: Cardiovascular and Peripheral Vascular Procedures

$3,000.00

This report presents procedure volumes forecasts for some of the most common cardiovascular and peripheral vascular surgical procedures performed in the five EU countries of France, Germany, Italy, Spain, and the UK (5EU). The forecast period covered by this report is for the years 2016 through 2021.
December 6, 2017
Find out more
ABBV-066
Read More
ABBV-066 (risankizumab; AbbVie/Boehringer Ingelheim) is a humanized anti-interleukin(IL)-23 subunit p19 monoclonal antibody that binds and neutralizes the p19 subunit of IL-23.
August 26, 2016
Find out more
Abemaciclib
Read More
Abemaciclib is a small molecule inhibitor of cyclin-dependent kinase (CDK)4 and CDK6 in Phase III development for non-small cell lung cancer and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer by Eli Lilly
November 14, 2016
Find out more
abexinostat
Read More
Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone.
March 6, 2019
Find out more
Abilify/Abilify Maintena
Read More
Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A receptor.
March 29, 2019
Find out more
Abraxane
Read More
Abraxane (nab-paclitaxel; Bristol-Myers Squibb) is a novel albumin-bound formulation of paclitaxel. Paclitaxel is an insoluble taxane classified as an anti-microtubule agent; it stops the growth of tumors by inhibiting mitosis during metaphase.
February 26, 2020
Find out more
Abuse-Deterrent Opioids Survey KOL Interview

$599.00

Biomedtracker performed a 5-question survey of 30 United States primary care physicians who currently treat patients with chronic pain and prescribe opioids to at least some of their patients with chronic pain to gauge current and future use of abuse-deterrent opioids to treat chronic pain.
March 9, 2017
Find out more
Access in Emerging Markets: HTA is Making Inroads

$2,995.00

Generally considered the domain of developed markets, health technology assessment (HTA) is increasingly being used by developing countries as a means of reconciling growing demand for access to health technologies with limited resources. Expanding public health insurance programs, coupled with aging populations and growing patient empowerment, have led in some cases to the fast establishment […]
November 2, 2016
Find out more
Access Trends in Emerging Markets

$3,000.00

This report provides an in-depth analysis of the market access climate in emerging pharmaceutical markets. Focusing in particular on the E7 countries (Brazil, Russia, India, China, Mexico, Indonesia, and Turkey), it charts recent developments, assesses their potential impact on market access, and pinpoints areas in which further change is anticipated.
February 20, 2019
Find out more
Accountable Care Organizations – What Impact on Pharma

$7,500.00

This strategy report focuses Accountable Care Organizations and what impact they will have on pharma including an evaluation of ACOs’ structures, sizes, cultures, and risks.
July 16, 2015
Find out more
Acne Prescribing Practices Pulse Survey

$599.00

We performed a survey of 10 dermatologists currently practicing in the US to gauge

prescribing practices for the treatment of acne.
November 29, 2016
Find out more
Actelion

$3,000.00

Analysis of Actelion’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
November 1, 2016
Find out more
Actemra
Read More
Actemra (tocilizumab; Roche/Chugai), known as RoActemra in Europe, is a first-in-class humanized interleukin-6 receptor monoclonal antibody.
March 24, 2015
Find out more
Activase
Read More
Activase (alteplase; Roche/Boehringer Ingelheim/Kyowa Hakko Kirin) is a recombinant tissue plasminogen activator, and is a manufactured version of the tissue plasminogen activating proteins found naturally in endothelial cells.
July 2, 2018
Find out more
Acute Lymphocytic Leukemia KOL Interview

$599.00

[Newer treatments] are definitely being used in the relapse population, and that’s where they made their mark like most other investigational agents for other cancers. I think the issue is that the response rate with initial induction therapy is so high. Whether or not there is going to be a maintenance-type study strategy, that’s a question with some of these therapies that are relatively low toxicity, but when you have a complete remission rate of 90-95%, and ALL’s not the most common disease – it’s a pretty rare cancer actually – that it’s going to be difficult to do large studies for indications in the randomized setting.
February 9, 2016
Find out more
Acute Myelogenous Leukemia (AML) KOL Interview

$599.00

Datamonitor interviewed three oncology specialists to determine the physicians’ views on marketed and pipeline therapies for Acute Myelogenous Leukemia. Two physicians were based in the US (Greater Midwest and Greater Boston areas) and one in the UK. The three interviews were combined into a single report.
August 19, 2016
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – Italy

$599.00

An interview with an Italian key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Onureg, Idhifa, Tibsovo, magrolimab, crenolanib, gilteritinib, and Iomab-B.
March 14, 2022
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – UK

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.
March 14, 2022
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include ASTX727, guadecitabine, idasanutlin, Iomab-B, oral azacitidine, pevonedistat, and Zeltherva.
April 1, 2020
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – US, East Coast

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.
April 1, 2020
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *